NCT00913237已完成1 期
Randomized, 2-way Crossover Bioavailability Study of Desipramine Hydrochloride 50 mg Tablets
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 36
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioavailability of Desipramine Hydrochloride 50 mg tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
2
Active Comparator
Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
干预措施: Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc) (Drug)
1
Experimental
Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
干预措施: Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 28 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride TabletsDepressionNCT00913822Sandoz36
已完成
1 期
Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting ConditionsHealthyNCT00974012Teva Pharmaceuticals USA24
已完成
1 期
Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting ConditionsHealthyNCT01132170Dr. Reddy's Laboratories Limited34
已完成
1 期
Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed ConditionsHealthyNCT01132196Dr. Reddy's Laboratories Limited34
已完成
1 期
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult ParticipantsHealthyNCT02117505Janssen Research & Development, LLC20